32 results about "Myelofibrosis" patented technology

Disclosed is a substance delivery carrier for an extracellular matrix-producing cell in the bone marrow, which comprises a retinoid. Also disclosed is an agent for treating myelofibrosis by utilizing a substance capable of regulating the activity or proliferation of an extracellular matrix-producing cell in the bone marrow.

The invention relates to clinical application of a substituted aryl hydrazone compound and a derivative thereof serving as an anti-tumor necrosis factor inhibitor. A test result shows that the compound has a lower cytotoxicity in animal bodies, so the medical compound is expected to be used as an anti-TNF-alpha and TNF-beta inhibitor in the clinical application and is mainly used for treating some TNF related immunological diseases such as rheumatic arthritis, inflammatory bowel diseases, diabetes, hematosepsis, psoriasis, ankylosing spondylitis and some communicable diseases including HIV. A current TNF related research also shows that the medical compound can be used for treating clinical blood and solid tumor such as myelodysplastic syndrome, myelofibrosis, acute bone marrow cell leucocythemia, acute / chronic graft-versus-host reaction, ovarian cancer, nephrocyte cancer and the like.

In part, the present disclosure relates methods for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or one or more complications of a myeloproliferative disorder. The present disclosure further relates methods for treating, preventing, or reducing the severity of a Janus kinase-associated disorder or one or more complications of a Janus kinase-associated disorder. In certain aspects the disclosure provides TβRII antagonists for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or a Janus kinase-associated disorder or one or more complications of a myeloproliferative disorder or a Janus kinase-associated disorder.

The invention provides a reagent and a method for detecting the ninth exon mutation of a CALR gene by using a Sanger sequencing technology. The reagent and the method are high in detection specificity, and the mutation types of insertion and deficiency of the ninth exon of CALR can be specially analyzed, so that the false positive problem is eliminated, and missing inspection of rare mutation can also be avoided. The reagent and the method can be used for clinically screening genes of patients suffering from primary thrombocythemia and primary myelofibrosis.

The invention provides a use of chlorogenic acid in preparing medicament for treating marrow fibrillation and also provides a pharmaceutical composition containing the chlorogenic acid as the active constituent.

The invention discloses a medicine composition for curing myelofibrosis and hepatofibrosis and a preparation method of the medicine composition. The main raw materials of the medicine composition include, by weight, 200-300 of vinegar turtles, 300-400 of fried peach seeds, 50-150 of cooked rhubarb, 100-200 of common burreed rhizome, 300-400 of leeches, 100-200 of rehmannia roots, 10-110 of human placenta, 10-110 of panax notoginseng and 50-150 of liquorice. The preparation method comprises steps of weighing the raw materials in accordance with the above prescription, uniformly mixing the raw materials through smashing and water-extraction concentration or a combination method of the smashing and the water-extraction concentration and obtaining the medicine composition. The medicine composition can soften hard lumps and dispel nodes, removes blood stasis for promoting tissue regeneration and nourishes blood and can be used for curing syndromes such as accumulation lumps under the rib side, sallowness, weakness, palpitation, shortness of breath, primary myelofibrosis, liver cirrhosis, hepatosplenomegaly and anemia which are caused by blood stasis and non-generation of new blood.

In part, the disclosure relates to methods of treating myeloproliferative disorders by administering one or more Serum Amyloid Protein (SAP) proteins. In certain aspects, the method further comprisesmonitoring treatment efficacy by measuring change in mutant allele burden. In certain aspects, the disclosure relates to methods of treating myelofibrosis in patient sub-populations who carry myelofibrosis-associated mutations in some of their cells by administering an SAP protein.

The invention discloses a leukemia-relevant circular circRNA-011235 gene and applications of the leukemia-relevant circular circRNA-011235 gene. According to the leukemia-relevant circular circRNA-011235 gene and the applications of the leukemia-relevant circular circRNA-011235 gene, the existence of the circRNA-011235 gene is proved first, through the detection on the expression condition of the gene in a patient under toal body irradiation, the result shows that the expression level of the circRNA-011235 gene is obviously increased. The marrow stroma cell transfected with the adenovirus vector with the overexpression of the circular circRNA-011235 gene is compared with a contrast marrow stroma cell transfected with a blank carrier, the result shows that the expression quantity of TGF-beta protein in the former cell is obviously increased, consequently, myelofibrosis is caused, then homing, self-renewal, proliferation and differentiation of hematopoietic cells are not facilitated, further, the curative effects of hematopoietic stem cell transplantation are influenced, therefore, the circular circRNA-011235 gene and the expression product of the circular circRNA-011235 gene can be taken as markers for predicating the hematopoietic stem cell transplantation curative effects, and can be taken as target genes and medicines for preparing leukemia medicines.

The invention disclosesan application of an IL-12p40 (- / -) IL-2R alpha (- / -) mouse model and belongs to the technical field of medical biology. Compared with IL-12p40 (- / -) IL-2R alpha (+ / -) mouse as a control mouse, an IL-12p40(- / -)IL-2R alpha(- / -) mouse is abnormal in a hematopoietic system in the following aspects: quantities of red blood cells and leukocytes in peripheral blood are reduced; CD4<+>T cells and CD8<+>T cells in bone marrow are abundantly infiltrated, proportion and quantity of LSK cells (Lin<->c-Kit<+>Sca-1<+> cells)are increased, hematopoietic capacity of the marrow declines, and reticular fibers appear in the marrow; splenomegaly occurs, and the spleen and the liver show extramedullary hematopoiesis. Therefore, the IL-12p40(- / -)IL-2R alpha(- / -) mouse can be takenas an animal model to be used for screening autoimmune myelofibrosis treatment drugs.

The invention discloses an application of a polypeptide and belongs to the field of biological pharmacy. The polypeptide is characterized in that the polypeptide contains the following structural domains: Pro-Arg-Cys-X-Y-Gly-Glu, wherein the X is Trp or Tyr and the Y is Arg or Cys; and Arg-Gly-Ala-Asp-Arg-Ala, or a sequence in which any amino acid in the above domains is mutated. The polypeptide can be used for treating various fibrotic diseases and symptoms including pulmonary fibrosis, hepatic fibrosis, myelofibrosis, renal fibrosis and myocardial fibrosis, skin fibrosis and pulmonary tissuepathological changes.

The invention discloses a traditional Chinese medicine composition for treating myelofibrosis caused by qi stagnation and blood stasis. The composition is characterized by being prepared from the following medicinal materials in parts by weight: 6-9 parts of curcuma zedoary, 12-15 parts of bauhinia seeds, 9-12 parts of undulata hand.-mazz, 15-18 parts of Chinese astilbe rhizome, 12-15 parts of kadsura coccinea, 6-9 parts of leeches, 15-20 parts of cantonese speranskia, 6-9 parts of vanieria thorn, 3-6 parts of fructus polygoni orientalis, 5-8 parts of trogopterus dung, 6-9 parts of Chinese ivy fruits, 1-3 parts of Piper sarmentosum Roxb, 3-6 parts of goldhair grmnopteris herb rhizome, 10-15 parts of Chinese ixora flower roots, 1-3 parts of citrus aurantium, 15-20 parts of ciliate leucas, 5-10 parts of semen aesculi and 5-7 parts of liquorice. The traditional Chinese medicine composition disclosed by the invention for treating myelofibrosis caused by qi stagnation and blood stasis is high in effective rate and reliable in curative effect, and myelofibrosis cured does not relapse.

The invention discloses a traditional Chinese medicine composition for treating myelofibrosis. The composition of the traditional Chinese medicine comprises white paeony roots, oysters, radix ophiopogonis, white atractylodes rhizome, radix rehmanniae, radix pseudostellariae, multiflower knotweed roots, radix trichosanthis, desertliving cistanche, turtle shells, red paeony roots or acceptable carriers in pharmacy. The invention further discloses a preparation method of the composition of the traditional Chinese medicine. The composition of the traditional Chinese medicine has the effects of softening hardness to dissipate stagnation, invigorating the circulation of blood, regulating the stagnation of qi and the like, is used for treating myelofibrosis clinically, has a good curative effect, and is free from toxic and side effects.

The invention provides a compound with a structure as shown in a general formula (I), a deuterated substance, a stereoisomer or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound and application of the compound and the deuterated substance, the stereoisomer or the pharmaceutically acceptable salt. The compound provided by the invention has a good PIM kinase inhibition effect, is a novel, high-activity and low-toxicity ideal PIM inhibitor, can be used for treating and / or preventing diseases such as hematoma such as acute myelogenous leukemia, myelofibrosis and chronic lymphocytic leukemia, solid tumors such as gastric cancer and prostate cancer, and has a wide application prospect.

The present invention relates to peptides that inhibit the excessive production and / or accumulation of an extracellular matrix in an organ or tissue. The peptides of the invention have the general formula sequence Xa-Leu-Gln-Gly-Xb (SEQ ID NO: 1) wherein Xa is selected from the group consisting of Pro-Gly, Gly and Ac-Gly and Xb is selected from the group consisting of Glu and Glu-NH2, which peptides are capable of inhibiting excessive production and excessive accumulation of extracellular matrix in organs or tissues in the form of linear peptides and cyclic peptides. In particular, the peptides disclosed herein are useful for the treatment of fibrotic disorders characterized by excessive accumulation of extracellular matrix, such as liver fibrosis, cirrhosis, pulmonary fibrosis, chronic respiratory failure, cardiac fibrosis, ischemic heart disease, heart failure, diabetic nephropathy, glomerulonephritis, myelofibrosis, and various types of cancers, such as liver fibrosis, liver cirrhosis, pulmonary fibrosis, chronic respiratory failure, cardiac fibrosis, ischemic heart disease, heart failure, diabetic nephropathy, glomerulonephritis, myelofibrosis, and the like. Such as breast cancer, uterine cancer, prostate cancer, pancreatic cancer, colon cancer, skin cancer, blood cell cancer, central nervous system cancer, fibromyoma, fibroma, fibroadenoma and fibrosarcoma.

The invention belongs to the technical field of pharmaceutical chemicals and in particular relates to a method for preparing a drug intermediate by catalyzing organic silicon supported ion liquid. Themethod comprises the following steps: preparing organic silicon supported alkaline ion liquid; connecting triethylene diamine with the mol amount by utilizing 1,4-dichlorobutane to provide a cation part of the alkaline ion liquid; then taking imidazolyl as anion to form ion liquid; supporting the prepared ion liquid by utilizing silica sol; in a supporting process, modifying by utilizing metal iodide to finally prepare the organic silicon supported alkaline ion liquid. The organic silicon supported alkaline ion liquid prepared by the method can be used for efficiently catalyzing condensationreaction of 5-nitrosalicylaldehyde and N-(2-chloroethyl)pyrrolidine to prepare a myelofibrosis treatment medicine Pacritinib intermediate, i.e., 5-nitro-2-[2-(pyrrolidine-1-yl)ethoxy]benzaldehyde; thedefect in a traditional production process that the production efficiency is low is overcome.

The invention discloses a traditional Chinese medicine composition for treating liver-kidney yin deficiency myelofibrosis, which is characterized by being prepared from the following medicinal materials in parts by weight: 5 parts of crotalaria ferruginea, 20 parts of herba lespedezae cuneatae, 10 parts of rhus chinensis, 15 parts of tolypanthus maclurei, 12 parts of taxillus delavayi, 13 parts of eclipta, 4 parts of deerhorn glue, 6 parts of morina chinensis, 8 parts of flatstem milkvetch seed, 10 parts of cordyceps sinensis, 10 parts of colla corii asini, 20 parts of herb of sessile didissandra, 10 parts of radix dipsaci, 30 parts of codonopsis convolvulacea, 30 parts of elaeagnus oldhamii maxim, 15 parts of diospyros lotus, 6 parts of poisonous buttercup fruit, 20 parts of bark of Chinese holly, 12 parts of herba cistanches and 15 parts of procumbent speedwell. The traditional Chinese medicine composition is used for treating the liver-kidney yin deficiency myelofibrosis, has high efficiency and a reliable curative effect, and the myelofibrosis does not recur after curing.

The invention discloses a traditional Chinese medicine composition for treating spleen-kidney yang deficiency type myelofibrosis. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 6 parts of elk's horns, 11 parts of morinda officinalis, 11 parts of fenugreek, 12 parts of all-grass of bulley herminium, 10 parts of herba epimedii, 7 parts of mantis egg-cases, 6 parts of human placenta, 8 parts of pleurotus pulmonarius, 7 parts of jizhangqi, 12 parts of glossy privet fruits, 16 parts of hill gooseberry seeds, 12 parts of hill gooseberry, 4 parts of black Chinese olive kernels, 12 parts of longflower stringbush roots, 7 parts of cornu cervi degelatinatum, 20 parts of aleuritopteris squamosa ching, 10 parts of rhamnella franguloides, 20 parts of bulbil and 10 parts of seeds of Chinese dodder. The traditional Chinese medicine composition disclosed by the invention is used for treating the spleen-kidney yang deficiency type myelofibrosis, is high in effective rate and is reliable in curative effect, so that the spleen-kidney yang deficiency type myelofibrosis hardly relapses.

To provide an antineutrophilia agent effective for treatment of development and progress of acute infections, collagen diseases (chronic rheumatoid arthritis, Wegener's granulomatosis and Behcet's disease), chronic obstructive pulmonary disease (COPD), chronic bronchitis, pulmonary emphysema, small airway disease, gout, Cushing's syndrome, myelofibrosis, neoplastic neutrophilia, polycythemia vera and diseases caused by administration of steroid drugs. An antineutrophilia agent containing a 3(2H)-pyridazinone compound represented by the formula (I) or a pharmaceutically acceptable salt thereof [wherein each of R1, R2 and R3 is independently a hydrogen atom or a C1-6 alkyl group, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen atom, trifluoromethyl or a hydrogen atom, and A is a C1-8 alkylene which may be substituted with a hydroxyl group].

The invention discloses a traditional Chinese medicine composition for treating myelofibrosis with blood stasis caused by qi-blood deficiency. The composition is characterized by being prepared from the following medicinal materials in parts by weight: 9 parts of Wedelia urticifolia DC, 10 parts of Melastoma dodecandrum Lour, 15 parts of russula rubra, 9 parts of myrtle, 12 parts of Eleutherine plicata Herb, 10 parts of palm sedge, 12 parts of acranthera,6 parts of liquorice, 11 parts of wild chervil, 10 parts of colla corii asini, 12 parts of siberian nitraria fruits, 8 parts of tsinling larkspur roots, 20 parts of fructus livistonae chinensis, 7 parts of chinese umbrellaleaf rhizome and roots, 15 parts of chinese siphonostegia herb, 10 parts of ligusticum wallichii, 12 parts of medicago falcate, 20 parts of Lespedeza tomentosa and 15 parts of polygala fallax hemsl. The traditional Chinese medicine composition disclosed by the invention for treating myelofibrosis with blood stasis caused by qi-blood deficiency is high in effective rate and reliable in curative effect and can avoid relapse of myelofibrosis after healing.

The invention discloses a medicine composition for treating chronic aplastic anemia. The medicine composition is prepared by the following main pharmacophore raw materials in parts by weight: 100-200 of thalattosaurus, 50-150 of herba epimedii, 250-400 of radix pseudostellariae, 150-250 of rehmannia, 250-350 of caulis spatholobi, and 150-250 of coloured malt. A preparation method comprises the following steps of: weighing the pharmacophore raw materials according to the formula; and uniformly mixing the pharmacophore raw materials through grinding, water extraction and concentration, or a manner of combining grinding and water extraction and concentration, thereby obtaining the end product. The medicine composition can be used for invigorating the kidney, supplying vital essence and marrow, and hematogenesis, is good for symptoms of various deficiency of essence and blood such as the deficiency of the kidney essence, marrow deficiency and blood disorders, and is used for treating aplastic anemia, myelodysplasia syndrome, leukemia, paroxysmal nocturnal hemoglobinuria, myelofibrosis, and patients with the symptoms caused by chemotherapy and the like.

The invention discloses a traditional Chinese medicine composition used for treating primary myelofibrosis. The traditional Chinese medicine composition comprises esliptae herba, the seeds of Chinesedodder, humulus scandens, fiveleaf akebia fruits, radix curcumae, Chinese sage herb, radix cudramiae, black nightshade herb, scorpio and pseudo-ginseng powder. The invention further provides a preparation method and application of the traditional Chinese medicine composition used for treating the primary myelofibrosis. According to the traditional Chinese medicine composition used for treating theprimary myelofibrosis, all traditional Chinese medicine materials mutually cooperate and act together according to the main, adjuvant, assistant and conductant compatibility so as to act on a focus and give play to the treatment effect on the primary myelofibrosis. Through clinical tests, it is shown that the traditional Chinese medicine composition has a good treatment effect on the primary myelofibrosis, the total effective rate reaches 80%, after being cured, the primary myelofibrosis is not prone to recurrence, and the traditional Chinese medicine composition is free of side and toxic effects and high in application value.

The present invention relates to a method for assisting the diagnosis of the condition of myelofibrosis (MF), a method for assisting the prognostic prediction of MF, and a method for monitoring the therapeutic effect on MF. The present invention also relates to an apparatus for executing these methods. Furthermore, the present invention relates to a marker for determining the condition of myelofibrosis.

The invention discloses a medicine composition for curing myelofibrosis and hepatofibrosis and a preparation method of the medicine composition. The main raw materials of the medicine composition include, by weight, 200-300 of vinegar turtles, 300-400 of fried peach seeds, 50-150 of cooked rhubarb, 100-200 of common burreed rhizome, 300-400 of leeches, 100-200 of rehmannia roots, 10-110 of human placenta, 10-110 of panax notoginseng and 50-150 of liquorice. The preparation method comprises steps of weighing the raw materials in accordance with the above prescription, uniformly mixing the raw materials through smashing and water-extraction concentration or a combination method of the smashing and the water-extraction concentration and obtaining the medicine composition. The medicine composition can soften hard lumps and dispel nodes, removes blood stasis for promoting tissue regeneration and nourishes blood and can be used for curing syndromes such as accumulation lumps under the rib side, sallowness, weakness, palpitation, shortness of breath, primary myelofibrosis, liver cirrhosis, hepatosplenomegaly and anemia which are caused by blood stasis and non-generation of new blood.

The invention belongs to the technical field of medicine, and relates to application of labetalol in the preparation of a medicine for preventing and treating fibrotic diseases. The labetalol is labetalol or a pharmaceutical derivative thereof. The fibrotic diseases include pulmonary fibrosis, hepatic fibrosis, renal fibrosis, cardiac fibrosis, endometrial fibrosis, ocular fibrosis, pancreatic fibrosis, splenic fibroplasia diseases, myelofibrosis diseases, or fibrosis-induced diseases. The labetalol can be combined with one or a plurality of pharmaceutical carriers to form a pharmaceutical composition. The labetalol or the pharmaceutical composition thereof can be used alone or combined with other drugs. Moreover, the labetalol has the advantages of remarkable curative effect, fewer toxicor side effects and safe use in the aspect of treating the fibrotic diseases.

The invention belongs to the technical field of medicine, relates to medical application of cathepsin inhibitors, and specifically relates to application of some cathepsin inhibitors in preparation ofmedicines for preventing or treating fibrotic diseases. The cathepsin inhibitor has a structure shown as follows, wherein R1 and R2 are described in the claims and the specification. The fibrotic diseases comprise pulmonary fibrosis, hepatic fibrosis, renal fibrosis, cardiac fibrosis, endometrial fibrosis, ocular fibrosis, pancreatic fibrosis, spleen fibrosis, myelofibrosis diseases or diseases induced by fibrosis. According to the invention, the cathepsin inhibitor is used alone or used in combination with other drugs.